Globus Medical Inc. Class A Common Stock vs Yum China Holdings Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Yum China Holdings Inc trades at $43.49 (market cap $14.46B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.71% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Yum China Holdings Inc for 77 Days on average.
| GMED | YUMC | |
|---|---|---|
Market Cap | $10.25B | $14.46B |
Volume | 1,108,124 | 996,391 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $57.95 |
52-Week Low | $58.33 | $39.98 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $9.76B | $15.37B |
Dividend Yield | — | 2.71% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
YUMC trades at $43.2, up 0.84% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $11.8B in 2025, with a net income margin of 7.84% and strong ROE of 17.5%. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bars to 300 locations.
The outlook is positive, supported by analyst consensus of 73.68% buy ratings and a projected 25.63% upside. Risks include execution of brand integration and competitive pressures in China's restaurant sector. Earnings growth and store expansion remain key catalysts for shareholder value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →